Alkermes Q2 rev. $390.7 mln, GAAP net income $87.1 mln, EPS $0.52.

• Alkermes reports Q2 2025 revenue of $390.7 million • GAAP net income at $87.1 million and diluted earnings per share at $0.52 • Company reiterates 2025 financial expectations • Alkermes to present Vibrance-1 results at World Sleep Congress • Strong performance across three proprietary products • Robust profitability and cash flow generation

Alkermes PLC (NASDAQ: ALKS) has reported its second-quarter (Q2) 2025 financial results, demonstrating robust performance across its portfolio of proprietary products. The company reported revenues of $390.7 million, GAAP net income of $87.1 million, and diluted earnings per share of $0.52 for the quarter ending June 30, 2025 [2].

Key highlights from the Q2 2025 financial results include:

- Revenue Growth: Alkermes reported a revenue of $390.7 million, up from $399.1 million in the previous quarter. This growth was driven by strong performance across all three proprietary products: VIVITROL®, ARISTADA®, and LYBALVI®. Specifically, LYBALVI® revenues grew by 18%, while ARISTADA® and VIVITROL® revenues grew by 18% and 9%, respectively [2].

- Profitability: The company's GAAP net income from continuing operations was $87.1 million, with a diluted earnings per share of $0.52. The company also reported strong EBITDA figures, with EBITDA from continuing operations at $114.7 million and adjusted EBITDA at $135.3 million [2].

- Cash Position: At the end of the second quarter, Alkermes recorded cash, cash equivalents, and total investments of $1.05 billion, compared to $916.2 million at the end of the first quarter [2].

- 2025 Financial Expectations: The company reiterated its financial expectations for the full year 2025, aligning with its previously stated projections. This includes revenue expectations of $1.39 billion and earnings per share of $1.15 [1].

- Clinical Trial Updates: Alkermes announced that it will present detailed results from its Vibrance-1 study, a phase 2 study of alixorexton (ALKS 2680) in narcolepsy type 1, at the upcoming World Sleep Congress. The company also mentioned that it will share topline results from its Vibrance-2 study in patients with narcolepsy type 2 later this fall [2].

Investor Reaction: Following the announcement, Alkermes' stock price saw a notable increase, reflecting investor confidence in the company's financial performance and the potential of its pipeline products.

Conclusion: Alkermes PLC's Q2 2025 financial results demonstrate strong performance and profitability across its proprietary product portfolio. The company's robust cash position and positive clinical trial updates further bolster its prospects for continued growth. Investors and financial professionals should closely monitor the upcoming conference call and presentation at the World Sleep Congress for more detailed insights into the company's performance and future plans.

References:
[1] https://finance.yahoo.com/news/alkermes-plc-alks-q2-2025-132339462.html
[2] https://www.marketscreener.com/news/alkermes-plc-reports-second-quarter-2025-financial-results-ce7c5fd9df8ff122